PL372529A1 - Atenuacja metapneumowirusa - Google Patents

Atenuacja metapneumowirusa

Info

Publication number
PL372529A1
PL372529A1 PL03372529A PL37252903A PL372529A1 PL 372529 A1 PL372529 A1 PL 372529A1 PL 03372529 A PL03372529 A PL 03372529A PL 37252903 A PL37252903 A PL 37252903A PL 372529 A1 PL372529 A1 PL 372529A1
Authority
PL
Poland
Prior art keywords
metapneumovirus
attenuation
Prior art date
Application number
PL03372529A
Other languages
English (en)
Inventor
Clive J. Naylor
Original Assignee
Lohmann-Animal Health Gmbh & Co.Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann-Animal Health Gmbh & Co.Kg filed Critical Lohmann-Animal Health Gmbh & Co.Kg
Publication of PL372529A1 publication Critical patent/PL372529A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18361—Methods of inactivation or attenuation
    • C12N2760/18362—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18562—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL03372529A 2002-05-16 2003-05-16 Atenuacja metapneumowirusa PL372529A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10221836A DE10221836A1 (de) 2002-05-16 2002-05-16 Attenuierung von Metapneumovirus

Publications (1)

Publication Number Publication Date
PL372529A1 true PL372529A1 (pl) 2005-07-25

Family

ID=29413891

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03372529A PL372529A1 (pl) 2002-05-16 2003-05-16 Atenuacja metapneumowirusa

Country Status (12)

Country Link
US (1) US20060002958A1 (pl)
EP (1) EP1503792A2 (pl)
JP (1) JP2005538702A (pl)
CN (1) CN1652819A (pl)
AU (1) AU2003240668A1 (pl)
BR (1) BR0310046A (pl)
CA (1) CA2484295A1 (pl)
DE (1) DE10221836A1 (pl)
IL (1) IL164698A0 (pl)
MX (1) MXPA04011226A (pl)
PL (1) PL372529A1 (pl)
WO (1) WO2003097089A2 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG149684A1 (en) 2001-01-19 2009-02-27 Vironovative Bv A virus causing respiratory tract illness in susceptible animals
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
KR101076102B1 (ko) 2002-02-21 2011-10-21 비로노바티브 비.브이. 메타뉴모바이러스에서 유래한 이종성 항원을 포함하는재조합 파라인플루엔자 바이러스 발현 시스템 및 백신
CA2523319A1 (en) 2003-04-25 2004-11-11 Medimmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
PT1789084E (pt) * 2004-09-09 2011-02-22 Novartis Vaccines & Diagnostic Redução de riscos iatrogénicos pontenciais associados às vacinas contra a gripe
WO2010077712A1 (en) * 2008-12-09 2010-07-08 Novavax, Inc. Bovine respiratory syncytial virus virus-like particle (vlps)
MX2012000036A (es) * 2009-06-24 2012-02-28 Glaxosmithkline Biolog Sa Vacuna.
US9512178B2 (en) * 2012-07-11 2016-12-06 Research Foundation For Mental Hygiene, Inc. Neurogenic brain-derived neurotrophic factor peptides
KR101560337B1 (ko) 2013-06-27 2015-10-19 주식회사 카브 신규한 조류메타뉴모바이러스 및 그 백신
WO2014208821A1 (ko) * 2013-06-27 2014-12-31 건국대학교기술지주 주식회사 신규한 조류메타뉴모바이러스 및 그 백신
MD3718565T2 (ro) 2015-10-22 2022-09-30 Modernatx Inc Vaccinuri împotriva virusului respirator
EP3551193A4 (en) 2016-12-08 2020-08-19 Modernatx, Inc. NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
RU2656188C1 (ru) * 2017-05-03 2018-06-04 Общество с ограниченной ответственностью "Анкрим" (ООО "Анкрим") Синтетическое анальгетическое средство пептидной природы и способ его применения
FR3084079A1 (fr) * 2018-07-23 2020-01-24 Universite Claude Bernard Lyon 1 Nouvelle souche virale attenuee et son utilisation en tant que vaccin
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
PH12021552736A1 (en) * 2019-05-20 2022-07-11 Valneva Se A subunit vaccine for treatment or prevention of a respiratory tract infection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083925A (en) * 1995-06-07 2000-07-04 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
SG149684A1 (en) * 2001-01-19 2009-02-27 Vironovative Bv A virus causing respiratory tract illness in susceptible animals

Also Published As

Publication number Publication date
WO2003097089A3 (de) 2004-02-05
IL164698A0 (en) 2005-12-18
CN1652819A (zh) 2005-08-10
JP2005538702A (ja) 2005-12-22
AU2003240668A1 (en) 2003-12-02
MXPA04011226A (es) 2005-06-20
DE10221836A1 (de) 2003-12-04
BR0310046A (pt) 2005-02-15
CA2484295A1 (en) 2003-11-27
WO2003097089A2 (de) 2003-11-27
EP1503792A2 (de) 2005-02-09
US20060002958A1 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
EP1549316A4 (en) HAMMER OF TFGbeta
PL375691A1 (pl) Imidazolopirydyny i sposoby ich wytwarzania i stosowania
GB0325192D0 (en) Method of use
EP1551398A4 (en) PYRAZOLOPYRIDINES AND METHODS OF MAKING AND USING THEM
IL164698A0 (en) Attenuation of metapneumovirus
IL165475A0 (en) Nitrooxyderivatives of eyclooxygenase-2 inhibitors
ZA200409686B (en) Bicyclic 6-aklylidene-penems as ?-lactamases inhibitors
HUP0500734A3 (en) Use of 2-alkoxyphenyl-substituted imidazotriazinones
AU2003297612A8 (en) 2-substituted-3-propenamide derivatives and methods of using the same
EP1488046A4 (en) CONSTRUCTION METHODS
GB0223276D0 (en) Cladding of rails
GB0210741D0 (en) Methods of therapy
AU2003298725A8 (en) Preparation of metallotexaphyrins
GB0221712D0 (en) Methods of treatment
EP1552803A4 (en) DIAPER
AU2003228532A8 (en) Methods of use of the enzymes of mycothiol synthesis
HUP0203929D0 (en) New use of substituted alkyl-piridazinone derivatives
AU2003243397A8 (en) Homo-camptothecin derivatives
PL356853A1 (pl) Zastosowanie bakteriofagów
IL165356A0 (en) Preparation of 4-haloalkylkylnicotinamides
SI1537210T1 (sl) Lazna oligonukleotidna inhibicija ekspresije CD40
TW566199U (en) Structure of earplug
GB0202120D0 (en) Acoustical system of closed type
TW567775U (en) Structure of hairtie
CA94393S (en) Set of furniture

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)